Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A

Replacement therapy in severe hemophilia A leads to factor VIII (FVIII) inhibitors in 30% of patients. Factor VIII gene (F8) mutation type, a family history of inhibitors, ethnicity and intensity of treatment are established risk factors, and were included in two published prediction tools based on...

Descripción completa

Detalles Bibliográficos
Autores principales: Bachelet, Delphine, Albert, Thilo, Mbogning, Cyprien, Hässler, Signe, Zhang, Yuan, Schultze-Strasser, Stephan, Repessé, Yohann, Rayes, Julie, Pavlova, Anna, Pezeshkpoor, Behnaz, Liphardt, Kerstin, Davidson, Julie E., Hincelin-Méry, Agnès, Dönnes, Pierre, Lacroix-Desmazes, Sébastien, Königs, Christoph, Oldenburg, Johannes, Broët, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6564000/
https://www.ncbi.nlm.nih.gov/pubmed/31194850
http://dx.doi.org/10.1371/journal.pone.0218258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6564000/
https://www.ncbi.nlm.nih.gov/pubmed/31194850
http://dx.doi.org/10.1371/journal.pone.0218258

Ejemplares similares